Yahong Pharmaceutical: Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on the progress of repurchasing the company\'s shares through centralized bidding
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on the progress of repurchasing the company\'s shares through centralized bidding transactions
Yahong Pharmaceutical: Corrective Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on the Resolutions of the 11th Meeting of the 2nd Board of Directors
Correction Notice of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on Resolutions of the 11th Meeting of the Second Board of Directors
Independent Financial Advisory Report of Shanghai Rongzheng Enterprise Consulting Service (Group) Co., Ltd. on matters relating to the granting of the 2024 Restricted Stock Incentive Plan by Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Legal Opinion of Beijing Jiayuan Law Firm on the Granting of the 2024 Restricted Stock Incentive Plan of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Announcement of Resolutions of the 11th Meeting of the Second Board of Directors of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement on the release of data related to the APL-1702 international multi-center phase III clinical trial at the 27th National Clinical Oncology Conference and the 2024 CSCO Academic Annual Conference
Inspection opinions of the board of supervisors of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on the 2024 Restricted Stock Incentive Plan incentive list (as of grant date)
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. 2024 Restricted Stock Incentive Plan Incentive List (as of grant date)
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on granting restricted shares to incentive recipients of the 2024 Restricted Stock Incentive Plan
Announcement of Resolutions of the 7th Meeting of the 2nd Board of Supervisors of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Yahong Pharmaceutical: Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the results of the Phase II clinical trial of APL-1202 oral combined with tirelizumab as a new adjuvant treatment for muscle-invasive bladder cancer
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the results of the Phase II clinical trial of APL-1202 oral combined with tiralizumab as a new adjuvant treatment for muscle-invasive bladder cancer
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. Investor Relations Activity Record Table_2024 Semi-Annual Results Briefing
CITIC Securities Co., Ltd.\'s 2024 semi-annual continuous supervision and follow-up report on Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Legal Opinion of Beijing Jiayuan Law Firm on the 2024 Second Extraordinary General Meeting of Shareholders of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Announcement of Resolutions of the 2024 Second Extraordinary General Meeting of Shareholders of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Self-inspection report of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on the 2024 Restricted Stock Incentive Plan insider\'s stock trading situation
Yahong Pharmaceutical: Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement on the release of data related to the APL-1702 International Multi-Center Phase III Clinical Trial at the 2024 International Photodynamic and Photodiagnostic Conference
No Data
No Data